Details of the Drug

General Information of Drug (ID: DMMJQSH)

Drug Name
Lanthanum carbonate
Synonyms Fosrenol; Foznol; Lambda; Lanthanum; Phosphate binding agent, Shire/Johnson Matthey; Project Lambda, Shire/Johnson Matthey
Indication
Disease Entry ICD 11 Status REF
Hypophosphatasia 5C64.3 Approved [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski):
0		 Molecular Weight 457.84
Topological Polar Surface Area Not Available
Rotatable Bond Count 0
Hydrogen Bond Donor Count 0
Hydrogen Bond Acceptor Count 9
ADMET Property
Bioavailability
The bioavailability of drug is 0.002% [2]
Half-life
The concentration or amount of drug in body reduced by one-half in 53 hours [3]
Metabolism
The drug is not metabolised [2]
Chemical Identifiers
Formula
C3La2O9
IUPAC Name
lanthanum(3+);tricarbonate
Canonical SMILES
C(=O)([O-])[O-].C(=O)([O-])[O-].C(=O)([O-])[O-].[La+3].[La+3]
InChI
InChI=1S/3CH2O3.2La/c3*2-1(3)4;;/h3*(H2,2,3,4);;/q;;;2*+3/p-6
InChIKey
NZPIUJUFIFZSPW-UHFFFAOYSA-H
Cross-matching ID
PubChem CID
168924
CAS Number
587-26-8
DrugBank ID
DB06792
TTD ID
D0H1LO
ACDINA ID
D00350

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphate (PHO) TTHOTF6 NOUNIPROTAC Modulator [1], [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Lanthanum carbonate (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Sarecycline DMLZNIQ Moderate Decreased absorption of Lanthanum carbonate due to formation of complexes caused by Sarecycline . Acne vulgaris [ED80] [5]
ABT-492 DMJFD2I Moderate Decreased absorption of Lanthanum carbonate due to formation of complexes caused by ABT-492. Bacterial infection [1A00-1C4Z] [5]
Omadacycline DMR2J95 Moderate Decreased absorption of Lanthanum carbonate due to formation of complexes caused by Omadacycline. Bacterial infection [1A00-1C4Z] [5]

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Magnesium stearate E00208 11177 lubricant
Silicon dioxide E00670 Not Available Anticaking agent; Opacifying agent; Viscosity-controlling agent
Talc E00520 16211421 Anticaking agent; Diluent; Glidant; lubricant
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Lanthanum carbonate 1000 mg tablet 1000 mg Chewable Tablet Oral
Lanthanum carbonate 500 mg tablet 500 mg Chewable Tablet Oral
Lanthanum carbonate 750 mg tablet 750 mg Chewable Tablet Oral
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 2004 approvals: the demise of the blockbuster. Nat Rev Drug Discov. 2005 Feb;4(2):93-4.
2 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
5 Canadian Pharmacists Association.